Revvity targets 2026 growth with multiomics, AI-powered base editing, NGS newborn screening, and immunotherapy advances.

DNAe, the Next-Generation Sequencing (NGS) company developing a transformative fully automated, sample-to-report diagnostics platform, today unveils a new Early Access Program, offering clinical ...

InnoCare Pharma’s next-generation TRK inhibitor zurletrectinib gets China NMPA approval to treat NTRK fusion-positive tumours: Beijing Saturday, December 13, 2025, 16:30 Hrs [IS ...

Zurletrectinib has been included in the “SPARK Program” by China’s National Medical Products Administration (NMPA), a pilot initiative to encourage the development of pediatric anti-tumor drugs.

Liquid biopsy is increasingly recognized as a promising tool for cancer detection and treatment monitoring, yet its ...

MUTE-Seq is a new liquid-biopsy method powered by an engineered ultra-precise CRISPR enzyme, FnCas9-AF2, which can ...

In a pilot study, researchers from North Carolina State University have found a novel kirkovirus that may be associated with colitis – and potentially small colon impactions – in horses. The study ...

In a new trial, patients with B-acute lymphoblastic leukemia (B-ALL) who had no evidence of remaining cancer cells after ...

Pillar Biosciences announced today an expansion of its existing laboratory access program with AstraZeneca for NGS-based ...

Foresight’s technology will be integrated into Natera’s Signatera platform and is expected to be launched for clinical use in ...

This study provides useful insights into addressing the question of whether the prevalence of autoimmune disease could be driven by sex differences in the T cell receptor (TCR) repertoire, correlating ...

The global digestive health market is booming, valued at $51bn (€43bn) and projected to reach $68bn by 2030 with an 8.3% CAGR ...